Does a GLP-1 help with PCOS acne and unwanted hair growth?
Key takeaways
Dr. Linda's take
Here is a question I get in some form almost every week: my skin and my chin hair bother me more than the number on the scale, so will this medication help with that?
I want to answer it honestly, because you have probably been promised things before. The short version is that the hormone lab work moves in the right direction, and the skin and hair evidence simply is not there yet. That is not the same as "it does not work." It means nobody has properly studied it. You deserve to know which of those two you are dealing with before you decide anything.
Why does PCOS cause acne and unwanted hair growth?
The engine behind both is androgen excess. In a patient with PCOS, the incidence of hyperandrogenism may be as high as 60 to 80%, and increased androgen levels affect ovulation and menstruation and also result in hirsutism and acne.
PCOS is also characterized by excessive androgen production by the ovaries, with insulin resistance and compensatory high insulin evident in the vast majority of affected individuals. That is why the metabolic side of PCOS and the skin and hair side tend to travel together. They are two windows onto the same room. We go deeper on that link in semaglutide and PCOS.
This matters for the question at hand. If androgens drive the symptom, then a treatment that lowers androgens is at least a reasonable thing to ask about. Reasonable to ask is where we start, not where we finish.
Do GLP-1 medications actually lower androgens in PCOS?
Yes, and this is the strongest part of the story.
In a meta-analysis of four randomized trials in women with PCOS and obesity, GLP-1 receptor agonists significantly reduced total testosterone compared with placebo, along with reductions in body mass index and waist circumference.
In a separate meta-analysis of nine randomized trials in just over a thousand women, exenatide lowered total testosterone and raised sex hormone-binding globulin more than metformin did, and exenatide combined with metformin reduced the free androgen index.
Two independent groups of trials, pointing the same direction. That is a genuine signal.
But read what those studies measured. They measured hormones in blood. They did not measure your face.
So does that mean a GLP-1 will clear my skin or slow hair growth?
This is where I have to be straight with you.
The most recent systematic review of GLP-1 receptor agonists in women with PCOS, pooling eleven randomized trials, found that evidence was insufficient to draw a conclusion regarding hirsutism, and concluded that benefits on metabolic, reproductive, or psychological outcomes remain uncertain due to low-quality data.
A larger review in the Annals of Internal Medicine looked at weight-loss interventions in PCOS across twenty-nine randomized comparisons. Of the studies reviewed, twelve used behavioral interventions, nine used GLP-1 agonists, and eight used other weight loss medications, and weight loss interventions were associated with significantly greater improvements in insulin resistance, free androgen index, and menstrual frequency, but there was no evidence that they were associated with clinically or statistically significant improvements in hirsutism.
Now, a crucial distinction that gets lost constantly. "No evidence of benefit" is not the same as "evidence of no benefit." The Annals authors said so themselves, noting the null hirsutism finding may be due to the limited power of the available data. The studies were small and short. Hair growth cycles are slow. It is entirely possible that a real effect exists and no one has run a trial long enough or large enough to see it.
What I cannot do is tell you it works when the trials that looked for it came back inconclusive.
What about acne specifically?
Thinner still. The only published data looking directly at semaglutide and acne is a small single-arm observational study in a dermatology clinic, not a controlled trial and not in women with PCOS, in which acne severity scores improved over 24 months alongside metabolic improvements.
One group, no comparison group, 110 people who finished, and the authors themselves called for further controlled studies. That is a hint that someone should run a real trial. It is not a reason to start a medication.
Is a GLP-1 approved for PCOS?
No. Semaglutide's approved uses under its FDA label are reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, reducing excess body weight and maintaining weight reduction long term, and treating noncirrhotic metabolic dysfunction-associated steatohepatitis. The words polycystic, PCOS, acne, and hirsutism do not appear in that label at all.
The tirzepatide label tells the same story. Tirzepatide is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Nothing about skin, hair, or PCOS.
So using either one for PCOS symptoms is off-label prescribing. Off-label is legal, common, and often appropriate, and it is also a conversation you are entitled to have out loud with a clinician rather than discover later.
What if I might want to get pregnant?
This deserves its own beat, because PCOS and fertility are so tangled together. We cover the timing in detail in do you need to stop a GLP-1 before trying to get pregnant with PCOS.
The semaglutide label directs that the medication be discontinued when pregnancy is recognized, and discontinued at least 2 months before a planned pregnancy because of the long half-life of semaglutide.
There is a second wrinkle. GLP-1 medications improve fertility in women with PCOS through weight reduction and enhanced insulin sensitivity, with meta-analyses showing higher spontaneous pregnancy rates, while gastrointestinal side effects may theoretically compromise the absorption of oral contraceptives. Read that twice. Fertility may go up at the same time that your existing contraception may become less reliable. That combination surprises people.
Note the word theoretically. The authors chose it deliberately and so do I.
What should I actually ask my clinician?
This is general education, not a plan for you specifically. But these are fair questions to bring:
If you are weighing whether any of this applies to you, our eligibility quiz is a starting point, and GLP-1 side effects with PCOS covers what to expect day to day.
The honest bottom line
If someone sells you these medications as a fix for your skin and unwanted hair, they are ahead of the evidence. The androgen markers move. The skin and hair outcomes have not been demonstrated, and the best available review says so plainly.
That is not a no. It is a not-yet, and there is a real difference. Many women with PCOS have excellent reasons to consider these medications that have nothing to do with this question. The point is to choose with your eyes open, for the reasons that are actually supported, rather than the ones that make the best advertisement.
You are allowed to want your skin to feel like yours again. You are also allowed to be told the truth about what will get you there.
Frequently asked questions
Does a GLP-1 clear PCOS acne?
That has not been shown. The only published data looking directly at semaglutide and acne is a small single-arm observational study in a dermatology clinic, not a controlled trial and not in women with PCOS, in which acne severity scores improved over 24 months alongside metabolic improvements. The authors themselves called for further controlled studies.
Does a GLP-1 reduce unwanted hair growth in PCOS?
The evidence does not support saying yes. The most recent systematic review of GLP-1 receptor agonists in women with PCOS, pooling eleven randomized trials, found that evidence was insufficient to draw a conclusion regarding hirsutism. That is different from proving it does not work; it means the question has not been answered.
Do GLP-1 medications lower testosterone in women with PCOS?
Yes. In studies of women with PCOS, GLP-1 receptor agonists lowered total testosterone compared with placebo. This is the best-supported part of the picture, though it measures hormones in blood rather than skin or hair.
Is a GLP-1 approved to treat PCOS?
No. Neither semaglutide nor tirzepatide is approved to treat PCOS, acne, or unwanted hair growth. Any use for those symptoms is off-label, which is legal and common but worth discussing openly with a clinician.
What if I want to get pregnant?
The semaglutide label directs that the medication be discontinued when pregnancy is recognized, and discontinued at least 2 months before a planned pregnancy because of the long half-life of semaglutide. This is a timing conversation to have with your clinician before starting.
Could a GLP-1 affect my birth control pill?
GLP-1 medications improve fertility in women with PCOS through weight reduction and enhanced insulin sensitivity, with meta-analyses showing higher spontaneous pregnancy rates, while gastrointestinal side effects may theoretically compromise the absorption of oral contraceptives. The word theoretically matters, and it is a reason to raise contraception with a clinician.
References
1. Annals of medicine (2024). The latest reports and treatment methods on polycystic ovary syndrome. PubMed PMID 38965663. https://pubmed.ncbi.nlm.nih.gov/38965663/ (Accessed 2026-07-17).
2. Nature reviews. Disease primers (2016). Polycystic ovary syndrome. PubMed PMID 27510637. https://pubmed.ncbi.nlm.nih.gov/27510637/ (Accessed 2026-07-17).
3. Journal of diabetes and its complications (2024). The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. PubMed PMID 39178623. https://pubmed.ncbi.nlm.nih.gov/39178623/ (Accessed 2026-07-17).
4. BMC endocrine disorders (2023). Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. PubMed PMID 37974132. https://pubmed.ncbi.nlm.nih.gov/37974132/ (Accessed 2026-07-17).
5. European journal of endocrinology (2026). GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis. PubMed PMID 41701618. https://pubmed.ncbi.nlm.nih.gov/41701618/ (Accessed 2026-07-17).
6. Annals of internal medicine (2024). Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials. PubMed PMID 39496172. https://pubmed.ncbi.nlm.nih.gov/39496172/ (Accessed 2026-07-17).
7. Cureus (2026). The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity. PubMed PMID 41669596. https://pubmed.ncbi.nlm.nih.gov/41669596/ (Accessed 2026-07-17).
8. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-17).
9. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception (2026). The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives. PubMed PMID 41860479. https://pubmed.ncbi.nlm.nih.gov/41860479/ (Accessed 2026-07-17).
10. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-17).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-17.*
Keep reading
What happens to your blood sugar if you stop a GLP-1 with prediabetes?
When people stopped a GLP-1 in the trials, weight came back and HbA1c rose in step with it. But the reversal was not automatic, and the famous 84.1% normoglycemia figure is an on-treatment number. Here is what the withdrawal data actually shows.
Does strength training protect muscle better than protein alone on a GLP-1?
Some of what you lose on a GLP-1 is lean mass, but dieting does the same thing. Training is the stronger and more direct lever, protein amplifies it, and the head-to-head trial is still running. Here is what the evidence actually supports.
Can a GLP-1 change your periods in perimenopause?
Nobody has run the trial on GLP-1s and menstrual bleeding in perimenopause, and perimenopause changes cycles by itself. Here is the indirect path through weight and ovulation, plus the one label warning about birth control that is worth acting on.
How much protein do you need on a GLP-1 to protect muscle?
There is no official protein requirement written for people taking a GLP-1, and the numbers in circulation are borrowed from weight-loss and sarcopenia research rather than proven in these patients. Here is what the trial body-composition data actually showed, and why a smaller appetite makes the target harder to hit.
Does a GLP-1 raise your risk of thyroid cancer?
Every GLP-1 label carries a boxed warning about thyroid C-cell tumors, and the fear it creates is real. Here is what the rodent studies actually showed, why the human question is still genuinely open, and who the labels say should not take these medicines.
Do you qualify for a GLP-1 if you have prediabetes but not diabetes?
Prediabetes is not an FDA-approved indication for any GLP-1, so qualification runs through the chronic weight management criteria instead. Here is how those criteria actually read on the current labels, and why prediabetes sits in a real but unofficial position.